Steroidal hormones and proliferation, differentiation and apoptosis in breast cells

Maturitas

Volumn 49, Issue 1, 2004, Pages 16-24

  Gompel, A ^a,b   Chaouat, M ^c   Hugol, D ^a   Forgez, P ^b  

^a HÔTEL DIEU   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c HÔPITAL ROTHSCHILD   (France)

Author keywords

Estrogen; Hormone replacement therapy; Progestin

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL] ESTRADIOL; 11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; 16ALPHA ETHYL 21 HYDROXY 19 NORPREGN 4 ENE 3,20 DIONE; 4 HYDROXYTAMOXIFEN; AROMATASE; CASPASE 3; CONJUGATED ESTROGEN; CYCLINE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; FULVESTRANT; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MITOGEN ACTIVATED PROTEIN KINASE; NORGESTREL; NORGESTRIENONE; ORAL CONTRACEPTIVE AGENT; PREGNANE DERIVATIVE; PROGESTERONE; PROMEGESTONE; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; STEROID HORMONE; TIBOLONE; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; APOPTOSIS; BREAST CANCER; BREAST CELL; CANCER RISK; CELL CYCLE; CELL CYCLE G1 PHASE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONFERENCE PAPER; DNA DAMAGE; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE MUTATION; GENOTYPE; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; LONG TERM EXPOSURE; MITOSIS INDEX; NONHUMAN; OBESITY; OVARIECTOMY; PHENOTYPE; PROTEIN PHOSPHORYLATION;

APOPTOSIS; BREAST; CELL PROLIFERATION; FEMALE; GONADAL STEROID HORMONES; HUMANS;

EID: 4444258773     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2004.06.009     Document Type: Conference Paper

References (40)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-1059.
2. Shairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc. 283:2000;485-491
3. WHI. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33.
4. WHI. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. J Am Med Assoc 2004;291:1701-12.
5. Magnusson C., Baron J.A., Correia N., Bergstrom R., Adami H.O., Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin- replacement therapy. Int J Cancer. 81:1999;339-344
6. Million women study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
7. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer form 54 epidemiological studies. Lancet 1996;347:1713-27.
8. Kaunitz A.M. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med. 41(Suppl 5):1996;419-425
9. Plu-Bureau G., Le M., Sitruk-Ware R., Thalabard J.C., Mauvais-Jarvis P. Progestogen use and risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br J Cancer. 70:1994;270-277
10. Longacre T.A., Bartow S.A. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol. 10:1986;382-393
11. Going J.J., Anderson T.J., Battersby S.C., Macintyre C.C.A. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol. 130:1988;193-204
12. Chang K.J., Fournier S., Lee Ti T.Y., de Lignières B., Linares G. Influence of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril. 63:1995;785-791
13. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963, 969.
14. Hofset L.J., Raafat A.M., Osuch J.R., Pathak D.R., Slmoski C.A., Haslam S.Z. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postemenopausal breast. J Clin Endocrinol Metab. 84:1999;4559-4565
15. Hargreaves D.F., Knox F., Swindell R., Potten C.S., Bundred N.J. Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy. Br J Cancer. 78:1998;945-949
16. Lundstrom E., Christow A., Kersemaekers W., et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol. 186:2002;717-722
17. Gompel A., Malet C., Spritzer P., Lalardrie J.-P., Kuttenn F., Mauvais-Jarvis P. Progestin effect on cell proliferation an 17 b-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J. Clin. Endocrinol. Metab. 63:1986;1174-1180
18. Gompel A., Chaouat M., Jacob D., Kloosterboer H.J., Perrot J.Y., Rostene W. Tibolone effects in breast cells in vitro studies. Fertil. Steril. 78:2002;351-359
19. Mc Manus M.J., Welsch C.W. The effect of estrogen, progesterone, thyroxine, and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice. Cancer. 54:1984;1920-1927
20. Musgrove E.A., Lee C.S.L., Sutherland R.L. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor, epidermal growth factor, c-fos, and c-myc genes. Mol Cell Biol. 11:1991;5032-5043
21. Vignon F., Bardon S, Chalbos D, Rochefort H. Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. J. Clin. Endocrinol. Metab. 56:1983;1124-1130
22. Musgrove E.A., Swarbrick A., Lee C S.L., Cornish A.L., Sutherland R.L. Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol Cell Biol. 18:1998;1812-1825
23. kip1. Mol Endocrinol. 11:1997;1593-1607
24. Richer J., Lange C.A., Manning N.G., Owen G., Powell R., Horwitz K.B. Convergence of progesterone with growth factor and cytokine signaling in breast cancer. J. Biol. Chem. 273:1998;31317-31326
25. Bassler R. Morphology of hormone induced structural changes in the female breast. Curr. Top. 53:1970;1-89
26. Grubbs J., Farnell D.R., Hill D.L., Mc Donough K.C. Chemo-prevention of N-nitro-N-methylurea-induced mammary cancers by pretreatment with 17 β-estradiol and progesterone. J. Natl. Cancer Inst. 74:1985;927-930
27. Gompel A., Chaouat M., Jacob D., Perrot J.Y., Kloosterboer H.J., Rostene W. In vitro studies of tibolone in breast cells. Fertil. Steril. 78:2002;351-359
28. Kandouz M., Lombet A., Perrot J-Y., et al. Proapoptotic effects of antiestrogens, progestines and androgen in breast cancer cells. J. Steroid Biochem. Mol. Bio. 69:1999;463-471
29. Gompel A., Somaï S., Chaouat M., et al. Hormonal regulation of apoptosis in breast cells. Hormonal regulation of apoptosis in breast cells and tissues. Steroids. 65:2000;593-598
30. Somaï S., Chaouat M., Jacob D., et al. Antiestrogens are pro-apoptotic in normal human breast epithelial cells. Int. J. Cancer. 105:2003;607-612
31. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homologue bax that accelerates programmed cell death. Cell. 74:1993;609-619
32. Slee E.A., Harte M.T., Kluck R.M., et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -7, -8, and -10 in a caspase-9 dependent manner. J. Cell Biol. 144:1999;281-292
33. Kandouz M., Siromachkova M., Jacob D., Marquet C., Therwath A., Gompel A. Antagonism between estradiol & progestin on bcl-2 expression in breast cancer cells. Int. J. Cancer. 68:1996;120-125
34. Teixeira C., Reed J.C., Pratt M.A.C. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 55:1995;3902-3907
35. Filardo E., Quinn J., Raymond Frackelton A., Bland K. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol. 16:2002;70-84
36. Ahola T., Alkio N., Manniven T., Ylikomi T. Progestin and G protein-coupled receptor 30 inhibit. Mitogen-activated protein kinase activity in MCF-7 breast cancer cells. Endocrinology. 143:2002;4620-4626
37. Ahola T., Manniven T., Alkio N., Ylikomi T. G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology. 143:2002;3376-3384
38. Simak A., Coombes R.C. Endocrine-responsive breast cancer and strategies for combatting resistance. Nat Rev/Cancer. 2:2002;101-115
39. Mote P.A., Bartow S., Tran N., Clarke C.L. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res. Treat. 72:2002;163-172
40. Kristensen V.N., Bressen-Dale A.L. Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutation Res. 462:2000;323-333